In vivo targeted CRISPR based loss-of-function mutations during neonatal mouse heart development Public Deposited

Downloadable Content

Download file
Last Modified
  • September 23, 2022
  • Qian, Yunzhe
    • ORCID: 0000-0002-8404-692
    • Affiliation: School of Medicine, Department of Pathology and Laboratory Medicine
  • Technologies that aim to alter DNA advances ever since the discovery of DNA double helix. Previous studies showed that Clustered Regularly Interspaced Short Palindromic Repeats pathway (CRISPR) can edit mammalian genomes in a cost-effective and user-friendly method1. Together with sgRNA (single-guide RNA), CRISPR/Cas9 can be effectively used in vivo to generate controlled mutations with specific cell targets2-3. By simply altering the sequence of sgRNA, we can reprogram Cas9 to target different genomic sites2-3,4. To achieve cardiomyocyte-specific knockout (KO) of the target genes with CRISPR/Cas9, we adopted CRISPR/Cas9 into AAV vector to create recombinant AAV serotype 9 (AAV9) to deliver single guide RNA (sgRNA) into the cardiomyocytes (CM), named CASAAV5. This project is a part of the on-going project in Qian lab. In this project, we will use in vivo perturb-seq to study CM maturation. Briefly, CASAAV will be used in a pooled approach to introduce mutations in each of the selected risk genes and interrogate each gene’s KO effect with single cell RNA-seq (scRNA-seq). We will knock out the risk genes identified from previous Genome-wide Association Studies (GWAS) of congenital and hypertrophic heart disease during neonatal heart maturation and study their function on CM maturation6. As the first in vivo Perturb-Seq on mouse heart development, the project could significantly deepen our understanding of CM maturation. Moreover, compared to classic approach to study gene’s function, in vivo Perturb-Seq can identify cardiac specific effects of genetic perturbations in a high-throughput manner7.
  • References 1. Doudna J. and Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096. 10.1126/science.1258096 2. Jin X, Simmones S, Guo A, Shetty A, Ko M, Nguyen L, Jokhi V, Robinson E, Oyler P, Curry N, Deangeli G, Lodato S, Levin J, Regev A, Zhang F, Arlotta P. In vivo Perturb- Seq reveals neuronal and glial abnormalities associated with autism risk genes. Science. 2020;370:aaz6063. 10.1126/science.aaz6063 3. Dixit A, Parnas O, Li B, Chen J, Fulco C, Jerby-Arnon L, Marjanovic N, Dionne D, Burks T, Raychowdhury R, Adamson B, Norman T, Lander E, Weissman J, Friedman N, Regev A. Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens. Cell. 2016;167: 1853-1866.e17. 4. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2016;337(6096):816-821. doi:10.1126/science.1225829 5. VanDusen N, Guo Y, Gu W, Pu W. CASAAV: A CRISPR-Based Platform for Rapid Dissection of Gene Function In Vivo. Curr. Protoc. Mol. Biol. 2017;120:31.11.1- 31.11.14. doi: 10.1002/cpmb.46. 6. Harper A, Goel A, Grace C. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet. 2021;53:135–142. 7. Carroll K, Makarewich C, McAnally J, Anderson D, Zentilin L, Liu N, Giacca M, Bassel-Duby R, Olson EN. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc. Natl. Acad. Sci. U. S. A. 2016;113(2):338–343. doi: 10.1073/pnas.1523918113.
Date of publication
Rights statement
  • In Copyright

This work has no parents.

In Collection: